Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

451 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Insulin patents and market exclusivities: unresolved issues--Authors' reply.
Luo J, Kesselheim AS. Luo J, et al. Lancet Diabetes Endocrinol. 2016 Feb;4(2):98-9. doi: 10.1016/S2213-8587(15)00494-5. Lancet Diabetes Endocrinol. 2016. PMID: 26825232 No abstract available.
Medical-process patents--monopolizing the delivery of health care.
Kesselheim AS, Mello MM. Kesselheim AS, et al. N Engl J Med. 2006 Nov 9;355(19):2036-41. doi: 10.1056/NEJMhpr063626. N Engl J Med. 2006. PMID: 17093256 No abstract available.
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.
Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Kesselheim AS, et al. JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758. JAMA. 2008. PMID: 19050195 Free PMC article. Review.
For editorials, we categorized authors' positions on generic substitution as negative, positive, or neutral. RESULTS: We identified 47 articles covering 9 subclasses of cardiovascular medications, of which 38 (81%) were randomized controlled trials (RCTs). ...
For editorials, we categorized authors' positions on generic substitution as negative, positive, or neutral. RESULTS: We identified 4 …
The Supreme Court, process patents, and medical innovation.
Kesselheim AS. Kesselheim AS. N Engl J Med. 2009 Dec 10;361(24):2303-6. doi: 10.1056/NEJMp0909658. N Engl J Med. 2009. PMID: 19923562 No abstract available.
Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH. Kesselheim AS, et al. Drugs. 2010 Mar 26;70(5):605-21. doi: 10.2165/10898530-000000000-00000. Drugs. 2010. PMID: 20329806 Free PMC article. Review.
We assessed characteristics of the studies and, for RCTs, extracted counts for patients whose seizures were characterized as 'controlled' and 'uncontrolled'. ...The observational study data may be explained by factors such as undue concern from patients or physician …
We assessed characteristics of the studies and, for RCTs, extracted counts for patients whose seizures were characterized as 'control …
State generic substitution laws can lower drug outlays under Medicaid.
Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS, Brookhart MA, Fischer MA. Shrank WH, et al. Health Aff (Millwood). 2010 Jul;29(7):1383-90. doi: 10.1377/hlthaff.2009.0424. Health Aff (Millwood). 2010. PMID: 20606192 Free PMC article.
Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS. Kesselheim AS. N Engl J Med. 2010 Nov 4;363(19):1855-62. doi: 10.1056/NEJMhle1002961. N Engl J Med. 2010. PMID: 21047231 No abstract available.
Improving antibiotic markets for long-term sustainability.
Kesselheim AS, Outterson K. Kesselheim AS, et al. Yale J Health Policy Law Ethics. 2011 Winter;11(1):101-67. Yale J Health Policy Law Ethics. 2011. PMID: 21381513 No abstract available.
451 results
Jump to page
Feedback